Ticagrelor and Clopidogrel

This entry refers to the pharmacological interventions evaluated in the **TIGER Study** (Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention), an investigator-initiated trial led by **Taipei Veterans General Hospital**. The study specifically compares two P2Y12 receptor antagonists: **ticagrelor** (developed by AstraZeneca) and **clopidogrel** (developed by Sanofi). Both drugs are antiplatelet agents used to prevent thrombotic events in patients with acute coronary syndromes, including ST-elevation myocardial infarction (STEMI). Ticagrelor is a direct-acting, reversible antagonist of the P2Y12 receptor, whereas clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form, which then binds irreversibly to the receptor. The TIGER study utilized contrast-enhanced magnetic resonance imaging (CE-MRI) to assess myocardial salvage and injury between these two treatment arms in the setting of primary percutaneous coronary intervention (PCI).

Brand names

BrilintaPlavixPossiaBrilique

Other names

TicagrelorClopidogrel